Literature DB >> 30231326

Ultimate Precision: Targeting Cancer but Not Normal Self-replication.

Vamsidhar Velcheti1, David Schrump1, Yogen Saunthararajah1.   

Abstract

Self-replication is the engine that drives all biologic evolution, including neoplastic evolution. A key oncotherapy challenge is to target this, the heart of malignancy, while sparing the normal self-replication mandatory for health and life. Self-replication can be demystified: it is activation of replication, the most ancient of cell programs, uncoupled from activation of lineage-differentiation, metazoan programs more recent in origin. The uncoupling can be physiologic, as in normal tissue stem cells, or pathologic, as in cancer. Neoplastic evolution selects to disengage replication from forward-differentiation where intrinsic replication rates are the highest, in committed progenitors that have division times measured in hours versus weeks for tissue stem cells, via partial loss of function in master transcription factors that activate terminal-differentiation programs (e.g., GATA4) or in the coactivators they use for this purpose (e.g., ARID1A). These loss-of-function mutations bias master transcription factor circuits, which normally regulate corepressor versus coactivator recruitment, toward corepressors (e.g., DNMT1) that repress rather than activate terminal-differentiation genes. Pharmacologic inhibition of the corepressors rebalances to coactivator function, activating lineage-differentiation genes that dominantly antagonize MYC (the master transcription factor coordinator of replication) to terminate malignant self-replication. Physiologic self-replication continues, because the master transcription factors in tissue stem cells activate stem cell, not terminal-differentiation, programs. Druggable corepressor proteins are thus the barriers between self-replicating cancer cells and the terminal-differentiation fates intended by their master transcription factor content. This final common pathway to oncogenic self-replication, being separate and distinct from the normal, offers the favorable therapeutic indices needed for clinical progress.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30231326     DOI: 10.1200/EDBK_199753

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  10 in total

1.  β-Hemoglobinopathies lead the way.

Authors:  Yogen Saunthararajah
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

2.  Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.

Authors:  Phaedon D Zavras; Aditi Shastri; Mendel Goldfinger; Amit K Verma; Yogen Saunthararajah
Journal:  Clin Cancer Res       Date:  2021-09-22       Impact factor: 13.801

3.  A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.

Authors:  Brian Hill; Deepa Jagadeesh; Brad Pohlman; Robert Dean; Neetha Parameswaran; Joel Chen; Tomas Radivoyevitch; Ashley Morrison; Sherry Fada; Meredith Dever; Shelley Robinson; Daniel Lindner; Mitchell Smith; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2020-12-14       Impact factor: 3.851

4.  Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells.

Authors:  Babal K Jha; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2020-12-14       Impact factor: 3.851

Review 5.  Targeting sickle cell disease root-cause pathophysiology with small molecules.

Authors:  Yogen Saunthararajah
Journal:  Haematologica       Date:  2019-08-08       Impact factor: 9.941

6.  Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies.

Authors:  Hassan Awada; Reda Z Mahfouz; Ashwin Kishtagari; Teodora Kuzmanovic; Jibran Durrani; Cassandra M Kerr; Bhumika J Patel; Valeria Visconte; Tomas Radivoyevitch; Alan Lichtin; Hetty E Carraway; Jaroslaw P Maciejewski; Yogen Saunthararajah
Journal:  Br J Haematol       Date:  2019-11-17       Impact factor: 6.998

Review 7.  From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia.

Authors:  Carmelo Gurnari; Maria Teresa Voso; Jaroslaw P Maciejewski; Valeria Visconte
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

8.  PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation.

Authors:  Xiaorong Gu; Francis Enane; Rita Tohme; Caroline Schuerger; Tomas Radivoyevitch; Yvonne Parker; Eric Zuberi; Bartlomiej Przychodzen; Babal Kant Jha; Daniel Lindner; Brian Rini; Yogen Saunthararajah
Journal:  Cell Rep       Date:  2021-09-21       Impact factor: 9.423

Review 9.  Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas.

Authors:  Nikolaus von Knebel Doeberitz; Daniel Paech; Dominik Sturm; Stefan Pusch; Sevin Turcan; Yogen Saunthararajah
Journal:  Int J Cancer       Date:  2022-06-16       Impact factor: 7.316

10.  Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation.

Authors:  Yogen Saunthararajah
Journal:  Haematologica       Date:  2020-09-01       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.